NCT04941183 is a Phase 1 clinical trial of NTR-441 in Covid19, sponsored by Neutrolis.

Who is sponsoring NCT04941183?

NCT04941183 is sponsored by Neutrolis.

What drugs are being tested in NCT04941183?

Interventions in NCT04941183: NTR-441, Placebo.

Is NCT04941183 still recruiting?

NCT04941183 is currently terminated. Last updated 19 January 2024.

Last reviewed 2024-01-19 · How we verify

NCT04941183

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1 Study to Assess Safety, Tolerability, PD, PK, Immunogenicity of IV NTR-441 Solution in Healthy Volunteers and COVID-19 Patients

Terminated Phase 1 Last updated 19 January 2024

What this trial tests

Phase 1 trial testing NTR-441 in Covid19 in 52 participants. Terminated before completion.

Timeline

14 April 2021

Primary endpoint
12 December 2022

6 June 2023

Quick facts

Lead sponsor	Neutrolis
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	triple
Primary purpose	treatment
Enrollment	52
Start date	14 April 2021
Primary completion	12 December 2022
Estimated completion	6 June 2023
Sites	4 locations across Austria, Ukraine

Drugs / interventions tested

NTR-441 — full drug profile →
Placebo

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

Neutrolis — full company profile →

Who can join

Adults 18 to 99, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This first-in-human clinical study is a Phase 1a/ 1b, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and PK/PD of NTR-441 in healthy subjects and patients with COVID-19 after single ascending IV infusion doses and multiple ascending IV infusion doses.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Intersecting Roles of Estrogens and Neutrophils in Modulating Innate Immunity in Cancer.
Wines-Samuelson M, Henson TR, Myers RJ, Hammes SR. · · 2026 · PMID 42193969 · DOI 10.3390/biom16050617

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Neutrolis trials

Trials by the same sponsor.

NCT07237659 — Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04941183 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Neutrolis
Last refreshed: 19 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04941183.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing